1. Home
  2. ARL vs SGMT Comparison

ARL vs SGMT Comparison

Compare ARL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARL
  • SGMT
  • Stock Information
  • Founded
  • ARL 1999
  • SGMT 2006
  • Country
  • ARL United States
  • SGMT United States
  • Employees
  • ARL N/A
  • SGMT N/A
  • Industry
  • ARL Building operators
  • SGMT
  • Sector
  • ARL Real Estate
  • SGMT
  • Exchange
  • ARL Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • ARL 245.7M
  • SGMT 238.7M
  • IPO Year
  • ARL N/A
  • SGMT 2023
  • Fundamental
  • Price
  • ARL $16.85
  • SGMT $8.67
  • Analyst Decision
  • ARL
  • SGMT Strong Buy
  • Analyst Count
  • ARL 0
  • SGMT 7
  • Target Price
  • ARL N/A
  • SGMT $26.57
  • AVG Volume (30 Days)
  • ARL 1.3K
  • SGMT 540.7K
  • Earning Date
  • ARL 11-06-2025
  • SGMT 11-12-2025
  • Dividend Yield
  • ARL N/A
  • SGMT N/A
  • EPS Growth
  • ARL N/A
  • SGMT N/A
  • EPS
  • ARL N/A
  • SGMT N/A
  • Revenue
  • ARL $48,139,000.00
  • SGMT N/A
  • Revenue This Year
  • ARL N/A
  • SGMT N/A
  • Revenue Next Year
  • ARL N/A
  • SGMT N/A
  • P/E Ratio
  • ARL N/A
  • SGMT N/A
  • Revenue Growth
  • ARL N/A
  • SGMT N/A
  • 52 Week Low
  • ARL $9.43
  • SGMT $1.73
  • 52 Week High
  • ARL $18.00
  • SGMT $11.41
  • Technical
  • Relative Strength Index (RSI)
  • ARL 59.21
  • SGMT 68.20
  • Support Level
  • ARL $15.63
  • SGMT $7.11
  • Resistance Level
  • ARL $16.34
  • SGMT $7.66
  • Average True Range (ATR)
  • ARL 0.39
  • SGMT 0.51
  • MACD
  • ARL -0.07
  • SGMT 0.19
  • Stochastic Oscillator
  • ARL 91.67
  • SGMT 99.58

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: